1. Introduction

State control over strategic genetic materials refers to the legal and regulatory authority of a government to control, regulate, protect, monitor, preserve, access, transfer, export, import and use genetic resources that have national, scientific, economic, environmental, agricultural, medical or biosecurity importance.

Strategic genetic materials may include:

Human genetic samples, DNA and genomic information.

Plant genetic resources, including indigenous seeds and rare crop varieties.

Animal genetic resources, including endangered and indigenous breeds.

Microorganisms, bacteria, viruses and fungi.

Genetic materials used in biotechnology and pharmaceutical research.

Pathogens and biological materials with potential biosecurity implications.

Genetic resources collected from forests, marine environments and biodiversity-rich regions.

Genetically modified organisms and gene-editing materials.

The central legal question is whether genetic materials should be treated as private property, national biological resources, common heritage, or resources subject to public-interest regulation.

Modern biotechnology law increasingly recognizes that governments may exercise sovereign regulatory authority over genetic resources while respecting individual rights, indigenous community interests, scientific freedom, international cooperation and environmental protection.

The distinction is important: State control over genetic resources does not automatically mean that the government owns every biological sample or has unrestricted authority over an individual's genetic information.

2. Meaning and Scope of Strategic Genetic Materials

Strategic genetic materials are biological substances or genetic information whose control is important for national security, public health, food security, biodiversity conservation, scientific development or economic independence.

State regulation can operate at several stages: collection, acquisition, storage, research, commercial exploitation, patenting, export, international transfer and eventual disposal.

3. Legal Foundations of State Control

A. Sovereignty over Natural Resources

The principle of permanent sovereignty over natural resources allows states to regulate the exploitation and conservation of resources within their jurisdiction.

In genetic-resource governance, this principle supports national rules governing access to biological materials, benefit-sharing arrangements and conservation obligations.

However, sovereignty is not unlimited. It must operate consistently with applicable international treaties, human rights obligations and domestic constitutional protections.

B. National Security and Biosecurity

Certain biological materials may create national security risks if improperly handled, transferred or commercially exploited.

Governments can therefore regulate:

Access to dangerous pathogens.

Storage of high-risk biological samples.

Export of sensitive genetic materials.

Transfers to foreign research institutions.

Dual-use biotechnology research.

Unauthorized genetic engineering.

Biological material repositories and laboratories.

C. Public Health and Food Security

Genetic materials can be essential to vaccine development, disease surveillance, agricultural resilience and epidemic preparedness.

States may establish national repositories, regulate strategic seed reserves and protect genetic resources necessary for future public-health emergencies.

D. Protection of Indigenous and Local Communities

Indigenous communities may possess traditional knowledge concerning medicinal plants, crop varieties and biological resources.

State regulation must therefore consider prior informed consent, customary rights, traditional knowledge and equitable benefit-sharing.

4. Indian Legal Framework Governing Strategic Genetic Materials

India regulates biological resources through a combination of environmental, biodiversity, intellectual property, agricultural, public-health and biosecurity laws.

A. Biological Diversity Act, 2002

The Biological Diversity Act, 2002 is the principal legislation governing access to biological resources and associated traditional knowledge in India.

Its three major objectives are:

Conservation of biological diversity.

Sustainable use of biological resources.

Fair and equitable sharing of benefits arising from their utilization.

The National Biodiversity Authority (NBA), State Biodiversity Boards and Biodiversity Management Committees form the institutional framework.

Important provisions:

The 2023 amendment changed the statutory definition of biological resources to exclude human genetic material. Consequently, human DNA should not automatically be treated as a biological resource regulated under this Act. Other applicable laws governing human samples, privacy, research ethics and medical information remain relevant.

The Biological Diversity Rules, 2024 came into force on 21 December 2024. The 2025 amendment to those Rules came into force on 1 November 2025.

National Biodiversity Authority+2

B. National Biodiversity Authority

The NBA is responsible for regulating relevant access, research-result transfers and intellectual-property activities under the Act.

Its functions include:

Granting or rejecting statutory approvals.

Determining benefit-sharing obligations.

Advising the Central Government on biodiversity conservation.

Protecting associated traditional knowledge.

Promoting sustainable use of biological resources.

Supporting compliance with international biodiversity obligations.

The NBA is particularly important when foreign biotechnology companies seek to use Indian biological resources for commercial research or pharmaceutical development.

National Biodiversity Authority+1

C. Protection of Plant Varieties and Farmers' Rights Act, 2001

This legislation balances breeders' intellectual-property interests with farmers' rights.

It recognizes:

Protection of registered plant varieties.

Farmers' rights to save, use, sow, resow, exchange and sell farm produce, subject to the statutory exception concerning branded seed.

Recognition and reward for farmers conserving genetic resources.

Protection of breeders' legitimate commercial interests.

It is particularly significant when the government seeks to protect indigenous seeds and strategic agricultural germplasm.

D. Patents Act, 1970

The Patents Act provides important safeguards against inappropriate privatization of biological resources.

Relevant provisions include:

Section 3(c): Excludes the discovery of living things or non-living substances occurring in nature from patentability.

Section 3(j): Excludes plants and animals in whole or any part thereof, seeds, varieties and species, and essentially biological processes, subject to the statutory wording.

Section 10: Prescribes requirements concerning patent specifications.

Section 64: Provides grounds for revocation of patents.

These provisions help prevent the patent system from being used to claim exclusive rights over naturally occurring biological materials merely because they have been discovered or isolated.

E. Other Relevant Indian Laws

5. International Legal Framework

A. Convention on Biological Diversity, 1992

The Convention on Biological Diversity (CBD) is a fundamental international instrument governing genetic resources.

Article 15 recognizes the sovereign rights of states over their natural resources and places authority to determine access to genetic resources with national governments, subject to national legislation.

Its major principles include:

National authority over access to genetic resources.

Prior informed consent where required.

Mutually agreed terms.

Fair and equitable benefit-sharing.

International scientific cooperation.

Article 15 does not establish unrestricted state ownership of every genetic sample. It establishes a framework for national regulation of access and utilization.

Treaties Database+1

B. Nagoya Protocol, 2010

The Nagoya Protocol strengthens the CBD framework through access and benefit-sharing requirements.

Its important provisions include:

Article 5: Fair and equitable benefit-sharing.

Article 6: Access to genetic resources.

Article 7: Traditional knowledge associated with genetic resources.

Article 12: Traditional knowledge and customary laws.

Article 15: Compliance with domestic access and benefit-sharing legislation.

Article 17: Monitoring the utilization of genetic resources.

For example, if a foreign pharmaceutical company obtains medicinal plant material from India and develops a commercial product, applicable access requirements and benefit-sharing arrangements may arise.

Benefits may include monetary payments, research collaboration, technology transfer, training and shared scientific results.

Convention on Biological Diversity+2

C. International Treaty on Plant Genetic Resources for Food and Agriculture, 2001

The International Treaty on Plant Genetic Resources for Food and Agriculture establishes a multilateral system for facilitated access to important agricultural genetic resources.

It covers 64 major food and forage crops through its multilateral system.

The treaty promotes:

Agricultural research.

Plant breeding.

Food security.

Conservation of crop diversity.

Benefit-sharing.

Farmers' rights.

It demonstrates that national control over strategic genetic resources can coexist with international sharing and cooperation.

FAO+1

6. Important Judicial Decisions and Case Laws

Courts have addressed state authority over biological resources, traditional knowledge, genetic information, privacy, patent rights and the commercialization of biological materials.

The following cases are particularly relevant.

Case 1. Divya Pharmacy v. Union of India (2018)

Highly relevant Indian precedent

Court: Uttarakhand High Court

Date: 21 December 2018

Case: Writ Petition (M/S) No. 3437 of 2016.

Facts:

Divya Pharmacy, an Indian pharmaceutical and Ayurvedic products manufacturer, challenged the demand for fair and equitable benefit-sharing imposed by the Uttarakhand Biodiversity Board.

The company argued that the benefit-sharing requirements under the Biological Diversity Act should not apply to an Indian company without foreign participation.

Legal issue:

Whether an Indian company commercially utilizing biological resources could be required to contribute to fair and equitable benefit-sharing.

Decision:

The High Court rejected the challenge and upheld the applicability of the benefit-sharing framework to the petitioner.

It recognized the authority of the State Biodiversity Board under the Biological Diversity Act, read with the relevant statutory provisions, to require benefit-sharing from Indian commercial users.

Legal principle:

Commercial exploitation of biological resources cannot automatically escape biodiversity benefit-sharing obligations merely because the user is an Indian company.

Importance:

This case establishes an important judicial foundation for India's regulatory authority over strategic biological resources and the equitable distribution of commercial benefits.

abs.nls.ac.in+2

Case 2. Justice K.S. Puttaswamy (Retd.) v. Union of India (2017)

Court: Supreme Court of India

Citation: (2017) 10 SCC 1.

Facts:

The case concerned the constitutional status of the right to privacy, particularly in the context of government collection and processing of personal and biometric information.

Legal issue:

Whether privacy is protected as a fundamental right under the Indian Constitution.

Decision:

The Supreme Court unanimously recognized privacy as a constitutionally protected fundamental right under Article 21 and other freedoms guaranteed by Part III.

The judgment established a threefold test for permissible state interference:

Legality: There must be a valid law.

Legitimate aim: The interference must pursue a legitimate state objective.

Proportionality: The measure must be proportionate to its objective.

Legal principle:

Government access to personal information must satisfy constitutional safeguards.

Importance for genetic materials:

Although the judgment did not directly determine ownership of genetic resources, its principles are highly relevant to national genomic databases, genetic identification systems, DNA repositories and government-controlled genetic information.

The government cannot claim unlimited authority to collect and use citizens' genetic information simply because it serves a national scientific or security objective.

Indian Kanoon+1

Case 3. Selvi v. State of Karnataka (2010)

Court: Supreme Court of India

Citation: (2010) 7 SCC 263.

Facts:

The case concerned the involuntary administration of scientific investigative techniques, including narco-analysis, polygraph examinations and brain electrical activation profile tests.

Legal issue:

Whether the compulsory use of such techniques violates constitutional protections against self-incrimination and personal liberty.

Decision:

The Supreme Court held that involuntary administration of these techniques violates constitutional protections under Articles 20(3) and 21.

Legal principle:

Scientific investigation cannot override bodily integrity, personal liberty and constitutional safeguards.

Importance for genetic governance:

The decision is relevant by analogy to compulsory genetic sampling and government-controlled DNA databases. It supports the principle that state investigations involving the human body must respect constitutional protections.

It should not be interpreted as a blanket prohibition on every legally authorized DNA test; DNA testing raises its own statutory, evidentiary and privacy considerations.

Case 4. Bhabani Prasad Jena v. Orissa State Commission for Women (2010)

Court: Supreme Court of India

Citation: (2010) 8 SCC 633.

Facts:

The dispute concerned the use of DNA testing to establish the paternity of a child.

Legal issue:

Whether courts should automatically order DNA testing whenever paternity is disputed.

Decision:

The Supreme Court emphasized that DNA testing is a sensitive matter and that courts must carefully consider privacy, necessity and the circumstances of the case.

Legal principle:

Scientific accuracy alone does not justify unrestricted genetic testing.

Importance:

This judgment is relevant to the regulation of human genetic samples and establishes an important judicial caution against unnecessary genetic investigations.

Case 5. Moore v. Regents of the University of California (1990)

Court: Supreme Court of California, United States

Citation: 51 Cal. 3d 120 (1990).

Facts:

John Moore's cells were used by medical researchers to develop a commercially valuable cell line without his informed consent concerning the researchers' financial interests.

Legal issue:

Whether the patient retained a property-based claim in his excised cells and whether the researchers had breached disclosure obligations.

Decision:

The court rejected Moore's conversion claim based on ownership of the excised cells but allowed his informed-consent and fiduciary-duty claims to proceed.

Legal principle:

Commercial use of biological materials raises important questions concerning consent, disclosure and research ethics, even when ownership claims are rejected.

Importance:

This case is relevant to the debate over state control, individual ownership and commercialization of human biological materials.

It also demonstrates why national regulation should distinguish between human genetic samples and naturally occurring biological resources governed by biodiversity legislation.

Case 6. Association for Molecular Pathology v. Myriad Genetics, Inc. (2013)

Court: Supreme Court of the United States

Citation: 569 U.S. 576 (2013).

Facts:

Myriad Genetics held patents concerning isolated DNA sequences associated with BRCA1 and BRCA2 genes.

The dispute concerned whether naturally occurring human DNA sequences could be patented merely because they had been isolated.

Legal issue:

Whether naturally occurring DNA becomes patentable subject matter through isolation.

Decision:

The US Supreme Court held that naturally occurring DNA segments are not patentable merely because they have been isolated.

However, synthetically created complementary DNA (cDNA) may be patentable, subject to the applicable patent requirements.

Legal principle:

Discovery of naturally occurring genetic information does not automatically create an exclusive intellectual-property right.

Importance:

The judgment is relevant to state regulation of genetic materials because it limits the privatization of naturally occurring genetic sequences through patent claims.

Case 7. Turmeric Patent Dispute (1995–1997)

Institution: United States Patent and Trademark Office.

Patent: US Patent No. 5,401,504.

Facts:

A US patent was granted for the use of turmeric in wound healing.

India challenged the patent through the Council of Scientific and Industrial Research (CSIR), submitting evidence of traditional Indian knowledge concerning turmeric's medicinal properties.

Outcome:

The patent was revoked in 1997 following the re-examination process because the claimed use lacked novelty in light of documented prior knowledge.

Legal principle:

Previously documented traditional knowledge can constitute prior art and prevent unjustified patent monopolies.

Importance:

The dispute encouraged India to strengthen the documentation and protection of traditional knowledge through initiatives such as the Traditional Knowledge Digital Library.

Press Information Bureau+2

Case 8. Neem Patent Opposition (W.R. Grace, European Patent Office, 2000)

Institution: European Patent Office.

Patent: EP0436257.

Facts:

A patent concerning fungicidal properties associated with neem-derived products was challenged by opponents, including Indian environmental organizations and farmers.

The challenge relied on evidence of prior traditional use of neem.

Outcome:

The patent was revoked by the European Patent Office in 2000.

Legal principle:

Traditional biological knowledge and prior use can prevent inappropriate monopolization of biological innovations.

Importance:

The dispute demonstrates why states need systems for documenting traditional knowledge and protecting biological resources against misappropriation.

Press Information Bureau+1

7. Constitutional Limitations on State Control

State authority over strategic genetic materials must remain consistent with constitutional protections.

In India, several constitutional provisions are particularly relevant.

Important constitutional conflicts

1. State security versus individual privacy

A government may require genetic identification for legitimate investigations, but indiscriminate collection and retention of DNA may violate privacy rights.

2. National interests versus scientific freedom

Strategic genetic resources may require regulatory approval, but excessive restrictions can obstruct legitimate scientific research and innovation.

3. State control versus indigenous rights

Government regulation must not disregard traditional knowledge, customary practices and legally recognized community interests.

4. Public ownership versus private commercial interests

States may regulate access and benefit-sharing without automatically eliminating lawful private property rights or valid intellectual-property protections.

8. Institutional Mechanisms for Controlling Strategic Genetic Materials

An effective national regulatory framework requires several institutions working together.

National strategic genetic-material governance structure

Central Government

National policy, security and international cooperation

National Biodiversity Authority

Access regulation and benefit-sharing

State Biodiversity Boards

State-level regulatory functions

Biodiversity Management Committees

Local biodiversity documentation and participation

Research institutions, gene banks and biological repositories

Secure storage, scientific research, documentation and monitoring

The institutional structure should provide:

Secure national genetic repositories.

Registration and traceability of biological samples.

Import and export monitoring.

Research licensing.

Transparent benefit-sharing arrangements.

Scientific risk assessment.

Protection against unauthorized transfers.

Independent regulatory oversight.

9. Major Legal Challenges

A. Genetic Biopiracy

Foreign companies may obtain genetic resources or associated traditional knowledge without complying with applicable access and benefit-sharing requirements.

The neem and turmeric disputes demonstrate the importance of protecting traditional knowledge.

B. Cross-Border Genetic Material Transfers

Genetic resources may be transferred through international research partnerships, commercial contracts, pharmaceutical collaborations and scientific databases.

This creates difficulties in determining:

Which country has authority over the material.

Whether prior informed consent was obtained.

Which country's benefit-sharing law applies.

Whether foreign patent applications comply with applicable requirements.

Whether subsequent commercial use is authorized.

C. National Security Risks

Certain genetic materials, especially dangerous pathogens, may present dual-use risks.

Governments must balance legitimate research with laboratory security, export controls and biological safety requirements.

D. Private Ownership and Commercialization

Disputes may arise between governments, research institutions, private companies, farmers and indigenous communities over access, ownership, patents and commercial benefits.

E. Lack of International Uniformity

Different countries have different regulatory approaches to genetic resources, human genetic information, biotechnology patents and biological sample exports.

This can create jurisdictional conflicts and enforcement difficulties.

10. Recommendations for Legal and Regulatory Reform

A comprehensive strategic genetic-material governance framework should incorporate the following reforms:

1. National genetic-resource inventory: Establish properly classified records of strategically important biological resources.

2. Secure biological repositories: Develop accredited storage institutions with traceability and access controls.

3. Transparent licensing: Require legally appropriate authorization for regulated collection, research, export and commercial utilization.

4. Community benefit-sharing: Ensure that indigenous and local communities receive appropriate benefits where their resources or traditional knowledge are used.

5. Genetic privacy safeguards: Establish strict safeguards for human DNA, genomic databases and personally identifiable genetic information.

6. Cross-border monitoring: Improve cooperation between customs, biodiversity regulators, research institutions and international enforcement agencies.

7. Patent examination safeguards: Improve the identification of traditional knowledge and naturally occurring biological materials during patent examination.

8. Independent regulatory review: Ensure that government decisions are evidence-based, proportionate and subject to judicial review.

9. Emergency access procedures: Create transparent rules for sharing strategically important biological materials during epidemics and other emergencies.

10. International cooperation: Strengthen compliance with the CBD, Nagoya Protocol and International Treaty on Plant Genetic Resources for Food and Agriculture.

11. Critical Legal Analysis

State control over strategic genetic materials presents a fundamental conflict between national sovereignty, scientific innovation, individual rights and global public interests.

On one side, governments must protect indigenous genetic resources, prevent biopiracy, secure dangerous biological materials and preserve biodiversity for future generations.

On the other side, excessive government control may restrict scientific collaboration, interfere with legitimate research, discourage biotechnology investment and undermine individual genetic privacy.

The case law establishes several important boundaries:

Divya Pharmacy supports statutory benefit-sharing obligations for commercial use of biological resources.

Puttaswamy establishes constitutional safeguards against disproportionate state interference with personal information.

Selvi protects bodily integrity and personal liberty against involuntary investigative techniques.

Moore illustrates the complexities of ownership and commercialization of human biological materials.

Myriad Genetics limits patent monopolies over naturally occurring human DNA.

The turmeric and neem disputes demonstrate the importance of protecting traditional biological knowledge.

The resulting legal position is that state regulatory authority must be distinguished from unrestricted ownership and control. National governments may regulate access to strategic genetic resources, but that authority must be exercised within the limits of constitutional law, applicable international obligations and the rights of affected communities and individuals.

12. Conclusion

State control over strategic genetic materials is an increasingly important area of biotechnology, environmental, constitutional and international law.

In India, the Biological Diversity Act, 2002 provides the principal framework for controlling access to biological resources, regulating their commercial utilization and ensuring fair and equitable benefit-sharing.

The CBD and Nagoya Protocol provide international support for national regulatory authority, while the FAO International Treaty promotes facilitated access to important agricultural genetic resources.

Judicial decisions such as Divya Pharmacy, Puttaswamy, Selvi, Moore and Myriad Genetics demonstrate that genetic-resource governance must balance national interests with individual rights, community interests and scientific development.

Ultimately, a legally sustainable system should protect strategic genetic materials without turning state sovereignty into unlimited governmental ownership or control over biological life.

13. Important Authorities and References

For further academic research, the following primary legal materials are useful:

National Biodiversity Authority – Official FAQs and legal framework.

Biological Diversity (Amendment) Act, 2023.

Convention on Biological Diversity – Article 15.

Nagoya Protocol – Access to Genetic Resources.

FAO International Treaty on Plant Genetic Resources.

Divya Pharmacy v. Union of India – Full Judgment.

Puttaswamy v. Union of India – Judgment.

Government of India – Turmeric and Neem Patent Disputes.

Academic research note: The turmeric and neem matters were patent opposition and revocation proceedings, not conventional court judgments. Similarly, Moore and Myriad are foreign judicial authorities and are persuasive comparative materials rather than binding Indian precedents.